Revlimid Fast Track Status Based On Randomized Trial Plan Later Skipped
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Celgene was granted a fast track designation for Revlimid based on plans to conduct a randomized trial that it later put off until after FDA approval, review documents show